Lipocine Inc. (LPCN) stock
Close on Nov 12, 2026Market cap $13.36MP/E –Yield –
Lipocine Inc. saw revenue fall 13.4% to $3.74M over the twelve months to Sep 30, 2026. At the latest close the market valued the company at $13.36M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $13.36M
- P/E ratio
- –
- Price to sales
- 3.57
- Price to book
- 0.63
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $3.74M
- Net income
- -$9.33M
- EPS, diluted
- -$1.29
- Book value per share
- $2.57
- Diluted shares
- 8M
Trading
- Next earnings
- Mar 9, 2027 (estimated, before the open)
- Previous close
- $1.59
- Open
- $1.58
- Day's range
- $1.51 – $1.63
- Volume
- 93,622
- Average volume (20 days)
- 229,590
- Beta (5 years)
- 0.65
- 52-week range
- $1.36 – $12.37
- RSI (14 days)
- 48.3
- Volatility (1 year)
- 109.7%
- Relative volume
- 0.07×
- WACC
- 8.1%
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | LPCN | S&P 500 | Difference | LPCN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -2.4% | -2.7% | +0.3 pts | ||
| 3 months | -21.4% | -1.7% | −19.6 pts | ||
| Year to date | -79.8% | +11.9% | −91.7 pts | ||
| 1 year | -44.5% | +12.0% | −56.5 pts | ||
| 3 years | -35.2% | +78.2% | −113.4 pts | -13.5% | +21.2% |
| 5 years | -92.0% | +73.2% | −165.2 pts | -39.6% | +11.6% |
| 10 years | -97.3% | +309.6% | −407.0 pts | -30.4% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Lipocine filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- News
- News
- News
- News
About Lipocine
Pharmaceutical Preparations
Lipocine Inc. is a biopharmaceutical company focused on developing oral formulations of poorly bioavailable drugs using its proprietary lipidic delivery technology platform. Its primary development programs target neurological and psychiatric central nervous system disorders, liver disease, and hormone supplementation. The company's approved product is TLANDO, an oral testosterone replacement therapy for adult males with hypogonadism. It also develops pipeline candidates such as LPCN 1154 for postpartum depression, alongside programs for major depressive disorder, essential tremor, epilepsy, and obesity management. Its customers and commercial partners include pharmaceutical companies that license and distribute its products.
Company profile, executives and historyLipocine stock: common questions
What is Lipocine's stock price?
LPCN closed at $1.62 on Nov 12, 2026, up 1.89% on the day. Over the past 52 weeks it traded between $1.36 and $12.37.
What is Lipocine's market cap?
Lipocine was worth $13.36M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is LPCN's P/E ratio?
Lipocine lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.29), so it has no meaningful P/E ratio.
How much revenue does Lipocine make?
Lipocine reported revenue of $3.74M for the twelve months to Sep 30, 2026, down 13.4% from a year earlier.
Does Lipocine pay a dividend?
No. Lipocine has not paid a cash dividend over the last twelve months.
When does Lipocine report earnings next?
Lipocine is expected to report Q4 FY2026 results on Mar 9, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has LPCN stock performed over the past year?
Including dividends, LPCN returned -44.5% over the past year, against +12.0% for the S&P 500.
How many LPCN shares are sold short?
0M shares were sold short at the latest FINRA report, 4.31% of the float, or 1.5 days of average trading volume.
Who are Lipocine's competitors?
Companies most similar to Lipocine by business, industry and size include VTGN, XENE, PRAX, ENSC, RANI.
See a number that looks wrong?